

Table S1. Proportion with anemia and mean value of hemoglobin and hematocrit, by cohort

Study	N	% Anemia	Hemoglobin, mean (SD)	Hematocrit, mean (SD)	Medication use availability		
					% Erythropoietin stimulating agent use	% IV iron supplement use	% oral iron supplement use
CKD Cohorts							
BC CKD	11655	6280 (54%)	12 (2)	37 (5)	NA	NA	NA
CanPREDDICT	2045	1206 (59%)	12 (2)	36 (5)	393 (19%)	477 (23%)	46 (2%)
CARE FOR HOME	371	71 (19%)	14 (2)	41 (4)	7 (2%)	4 (1%)	6 (2%)
CCF	12696	5307 (42%)	13 (2)	39 (5)	NA	NA	NA
CKD-JAC	2639	1659 (63%)	12 (2)	36 (5)	350 (13%)	21 (1%)	215 (8%)
CRIB	364	218 (60%)	12 (2)	NA	35 (10%)	NA	NA
GCKD	5127	1217 (24%)	14 (2)	NA	123 (2%)	NA	NA
Geisinger CKD†	19008	7696 (40%)	13 (2)	33 (6)	35 (0%)	30 (0%)	1293 (7%)
Gonryo	3044	1113 (37%)	13 (2)	38 (6)	200 (7%)	NA	NA
MASTERPLAN	670	236 (35%)	13 (2)	39 (37)	57 (9%)	NA	2 (6%)
MDRD	1719	602 (35%)	13 (2)	38 (4)	NA	NA	NA
MMKD	202	58 (29%)	13 (2)	40 (6)	NA	NA	NA
Mt Sinai BioMe CKD†	1931	1103 (57%)	12 (2)	36 (6)	69 (4%)	9 (0%)	275 (14%)
PSP-CKD	2223	762 (34%)	13 (2)	NA	36 (2%)	NA	NA
RCAV	108044	43385 (40%)	13 (2)	NA	421 (0%)	20 (0%)	4048 (4%)
RENAAL	1510	791 (52%)	13 (2)	38 (6)	NA	NA	NA
SCREAM CKD†	30209	10291 (34%)	13 (2)	NA	935 (3%)	186 (1%)	1407 (5%)
SRR-CKD	3032	1841 (61%)	12 (2)	NA	623 (21%)	105 (3%)	346 (11%)
Sunnybrook	2822	1048 (37%)	13 (2)	NA	NA	NA	NA
Subtotal	209311	84882 (41%)	13 (2)	36 (7)	3287 (2%)	853 (1%)	7638 (5%)
General Population							
Aichi	4987	285 (6%)	15 (1)	NA	NA	NA	NA
BIS	1995	354 (18%)	14 (1)	41 (4)	4 (0%)	1 (0%)	24 (1%)
CIRCS	11475	1422 (12%)	14 (2)	41 (5)	NA	NA	NA
Gubbio	1684	33 (2%)	15 (1)	43 (4)	0 (0%)	0 (0%)	34 (2%)
IPHS	97740	11378 (12%)	14 (1)	41 (4)	NA	NA	NA
JMS	5091	689 (14%)	14 (2)	42 (4)	NA	NA	NA
KHS	243716	16043 (7%)	14 (2)	43 (5)	NA	NA	NA
MRC	12101	2372 (20%)	13 (1)	NA	NA	NA	NA
NHANES	51434	4928 (10%)	14 (2)	42 (4)	NA	NA	NA

NIPPON DATA90	7612	1048 (14%)	14 (2)	44 (5)	NA	NA	NA
NIPPON DATA2010	2730	338 (12%)	14 (2)	42 (4)	NA	NA	NA
Ohasama	1926	389 (20%)	13 (1)	40 (4)	NA	NA	NA
REGARDS	19070	2657 (14%)	14 (1)	40 (4)	NA	NA	NA
RSIII	3525	160 (5%)	14 (1)	45 (4)	NA	NA	NA
Taiwan MJ	501646	36932 (7%)	14 (2)	42 (4)	NA	NA	NA
Takahata	3523	406 (12%)	14 (1)	41 (4)	NA	NA	NA
Subtotal	970255	79434 (8%)	14 (2)	42 (5)	4 (0%)	1 (0%)	58 (2%)
High Risk Cohorts							
Geisinger	46072	10189 (22%)	14 (2)	35 (6)	41 (0%)	37 (0%)	1909 (4%)
Maccabi	253333	33080 (13%)	14 (1)	42 (4)	326 (0%)	2 (0%)	2828 (1%)
Mt Sinai BioMe	4346	1764 (41%)	13 (2)	38 (5)	72 (2%)	8 (0%)	462 (11%)
Pima	5058	506 (10%)	NA	42 (5)	NA	NA	NA
SCREAM	232861	27342 (12%)	14 (1)	NA	999 (0%)	264 (0%)	3411 (1%)
SMART	3684	378 (10%)	14 (1)	42 (4)	NA	NA	NA
Subtotal	545354	73256 (13%)	14 (2)	41 (5)	1438 (0%)	311 (0%)	8610 (2%)
General population/ high risk subtotal	1515609	152690 (10%)	14 (2)	42 (5)	1442 (0%)	312 (0%)	8668 (2%)

Total† 1673772

Anemia: Hemoglobin <13g/dL for male, <12g/dL for female; Hematocrit <39% for male, <36% for female

† CKD population from three administrative high risk cohorts, not included in the total N